Preventing Nosocomial MDR TB Transmission in sub Saharan Africa: Where Are We at? | Zendy

Sonia Me | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Preventing Nosocomial MDR TB Transmission in sub Saharan Africa: Where Are We at?

Author(s) -

Sonia Me

Publication year - 2013

Publication title -

global journal of health science

Language(s) - English

Resource type - Journals

eISSN - 1916-9744

pISSN - 1916-9736

DOI - 10.5539/gjhs.v5n4p200

Subject(s) - medicine , tuberculosis , transmission (telecommunications) , infection control , intensive care medicine , drug resistance , sputum , medline , human immunodeficiency virus (hiv) , multi drug resistant tuberculosis , clinical trial , drug resistant tuberculosis , protocol (science) , pediatrics , immunology , mycobacterium tuberculosis , alternative medicine , pathology , electrical engineering , microbiology and biotechnology , political science , law , engineering , biology

In sub Saharan Africa, the cocktail of many advanced HIV-infected susceptible hosts, poor TB treatment success rates, a lack of airborne infection control, limited drug-resistance testing (DST) have resulted in HIV-infected individuals being disproportionately represented in Multi drug resistant Tuberculosis (MDR-TB) cases. The prevailing application of the WHO re-treatment protocol indiscriminately to all re-treatment cases sets the stage for an increase in mortality and MDR-TB nosocomial transmission.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research